p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer

Journal of Surgical Oncology

Volumn 82, Issue 2, 2003, Pages 111-120

  Dong, Ming ^a,b   Nio, Yoshinori ^a   Yamasawa, Kunihiro ^a   Toga, Tomoko ^a   Yue, Lishuang ^a,b   Harada, Takayuki ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Chemotherapy; p53; Pancreatic cancer; Point mutation; Polymorphism

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN C; PROTEIN P53; UFT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC POLYMORPHISM; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE AMPLIFICATION; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREATECTOMY; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; SEQUENCE ANALYSIS, DNA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037311096     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/jso.10186     Document Type: Article

References (64)

1. Lieberman MD, Paty P, Li XK, et al.: Elevation of intracellular cyclic adenosine monophosphate inhibits the epidermal growth factor signal transduction pathway and cellular growth in pancreatic adenocarcinoma cell lines. Surgery 1996;120:354-359.
2. Suwa H, Yoshimura T, Yamaguchi N, et al.: K-ras and p53 alterations in genomic DNA and transcripts of human pancreatic adenocarcinoma cell lines. Jpn J Cancer Res 1994;85:1005-1014.
3. Casey G, Yamanaka Y, Friess H, et al.: p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-160.
4. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331.
5. Harris CC: p53: At the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1981.
6. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991;351:453-456.
7. Bates S, Vousden KH: p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996;6:12-18.
8. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78:580-591.
9. Nakamori S, Yashima K, Murakami Y, et al.: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res 1995;86:174-181.
10. Andre T, Balosso J, Louvet C, et al.: Adenocarcinoma of the pancreas. Diagnosis and evaluation [in French]. Presse Med 1998;27:537-538.
11. Barton CM, Staddon SL, Hughes CM, et al.: Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer 1991;64:1076-1082.
12. Ruggeri B, Zhang SY, Caamano J, et al.: Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-1511.
13. Scarpa A, Capelli P, Mukai K, et al.: Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993;142:1534-1543.
14. Cascallo M, Calbo J, Gelpi JL, et al.: Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000;7:545-556.
15. Lu Z, Kleeff J, Shrikhande S, et al.: Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas 2000;21:240-247.
16. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-139.
17. Hickman JA, Beere HM, Wood AC, et al.: Mechanisms of cytotoxicity caused by antitumour drugs. Spec No: 553-561. Toxicol Lett 1992; 64-65.
18. Clarke AR, Purdie CA, Harrison DJ, et al.: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
19. Pocard M, Bras-Goncalves R, Hamelin R, et al.: Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: Influence of P53 status. Anticancer Res 2000;20:85-90.
20. Fan S, El-Deiry WS, Bae I, et al.: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-5830.
21. Benhattar J, Cerottini JP, Saraga E, et al.: p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996;69:190-192.
22. Bottini A, Berruti A, Bersiga A, et al.: p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000;6:2751-2758.
23. Cabelguenne A, Blons H, de Waziers I, et al.: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. J Clin Oncol 2000;18:1465-1473.
24. Cote RJ, Esrig D, Groshen S, et al.: p53 and treatment of bladder cancer. Nature 1997;385:123-125.
25. Nio Y, Dong M, Uegaki K, et al.: p53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas. Anticancer Res 1998;18:3773-3779.
26. Dong M, Nio Y, Sato Y, et al.: Comparative study of p53 expression in primary invasive ductal carcinoma of the pancreas between Chinese and Japanese. Pancreas 1998;17:229-237.
27. Dergham ST, Dugan MC, Sarkar FH, et al.: Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. J Hepatobiliary Pancreat Surg 1998;5:269-272.
28. Gansauge F, Gansauge S, Link KH, et al.: p53 in relation to therapeutic outcome of locoregional chemotherapy in pancreatic cancer. Ann N Y Acad Sci 1999;880:281-287.
29. Sourvinos G, Rizos E, Spandidos DA: p53 Codon 72 polymorphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncology 2001;37:572-578.
30. Summersgill KF, Smith EM, Kirchner HL: p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 2000;90:334-339.
31. Bastiaens MT, Struyk L, Tjong-A-Hung SP, et al.: Cutaneous squamous cell carcinoma and p53 codon 72 polymorphism: A need for screening? Mol Carcinog 2001;30:56-61.
32. Hamel N, Black MJ, Ghadirian P, et al.: No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. British Journal of Cancer 2000;82:757-759.
33. Nakano Y, Naoe T, Kiyoi H, et al.: Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia. Leukemia Res 2000;24:349-352.
34. Fan R, Wu MT, Miller D, et al.: The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1037-1042.
35. Kawaguchi H, Ohno S, Araki K, et al.: p53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Res 2000;60:2753-2755.
36. Kim JW, Roh JW, Park NH, et al.: Polymorphism of TP53 codon-72 and the risk of cervical cancer among Korean women. Am J Obstet Gynecol 2001;184:55-58.
37. Nishikawa A, Fujimoto T, Akutagawa N, et al.: p53 polymorphism (codon-72) has no correlation with the development and the clinical features of cervical cancer. Int J Gynecol Cancer 2000;10:402-407.
38. Yang YC, Chang CL, Chen ML: Effect of p53 polymorphism on the susceptibility of cervical cancer. Gynecol Obstet Invest 2001;51:197-201.
39. Zehbe I, Voglino G, Wilander E, et al.: p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 2001;61:608-611.
40. Suzuki Y, Sekiya T, Hayashi K. Allele-specific polymerase chain reaction: A method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem 1991;192:82-84.
41. Meinhold-Heerlein I, Ninci E, Ikenberg H, et al.: Evaluation of methods to detect p53 mutations in ovarian cancer. Oncology 2001;60:176-188.
42. Sobin LH, Wittekind C: "TNM Classification of Malignant Tumours." 5th ed. New York: John Wiley & Sons; 1997. 87-90.
43. Goelz SE, Hamilton SR, Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 1985;130:118-126.
44. Li Y, Bhuiyan M, Vaitkevicius VK, et al.: Structural alteration of p53 protein correlated to survival in patients with pancreatic adenocarcinoma. Pancreas 1999;18:104-110.
45. Gretarsdottir S, Tryggvadottir L, Jonasson JG, et al.: TP53 mutation analyses on breast carcinomas: A study of paraffinembedded archival material. Br J Cancer 1996;74:555-561.
46. Chappuis PO, Estreicher A, Dieterich B, et al.: Prognostic significance of p53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-593.
47. Murakami I, Hiyama K, Ishioka S, et al.: p53 gene mutations are associated with shortened survival in patients with advanced non-small cell lung cancer: An analysis of medically managed patients. Clin Cancer Res 2000;6:526-530.
48. Uchida T, Wada C, Ishida H, et al.: p53 mutations and prognosis in bladder tumors. J Urol 1995;153:1097-1104.
49. Soong R, Powell B, Elsaleh H, et al.: Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000;36:2053-2060.
50. Rowan S, Ludwig RL, Haupt Y, et al.: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996;15:827-838.
51. Taubert H, Meye A, Wurl P: Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients. Cancer Res 1996;56:4134-4136.
52. Kawesha A, Ghaneh P, Andren-Sandberg A, et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16 (INK not expression of p53, p16 (INKB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 2000;89:469-474.
53. Malkin D, Li FP, Strong LC, et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
54. Ranzani GN, Luinetti O, Padovan LS, et al.: p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 1995;4:223-231.
55. Rozenblum E, Schutte M, Goggins M, et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-1734.
56. Yamaguchi K, Chijiiwa K, Noshiro H, et al.: Ki-ras codon-12 point mutation and p53 mutation in pancreatic diseases. Hepatogastroenterology 1999;46:2575-2581.
57. Dong M, Nio Y, Tamura K, et al.: Ki-ras point mutation and p53 expression in human pancreatic cancer: A comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev 2000;9:279-284.
58. Fan S, Smith ML, Rivet DJ II, et al.: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995;55:1649-1654.
59. Grundei T, Vogelsang H, Ott K, et al.: Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 2000;6:4782-4788.
60. Huang S, Liu LN, Hosoi H, et al.: p53/p21 (CIP1) cooperate in enforcing rapamycin-induced G (1) arrest and determine the cellular response to rapamycin. Cancer Res 2001;61:3373-3381.
61. Koechli O, Schaer GN, Seifert B, et al.: Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-1648.
62. Waldman T, Lengauer C, Kinzler KW, et al.: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381:713-716.
63. Petty RD, Cree IA, Sutherland LA, et al.: Expression of the p53 tumour suppressor gene product is a determinant of chemo-sensitivity. Biochem Biophys Res Commun 1994;199:264-270.
64. Mueller H, Eppenberger U: The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16:3845-3848.